Thymosin alpha 1 (thymalfasin, Ta1), the active ingredient in ZADAXIN , is a peptidic biological response modifier which activates various cells of the immune system. Ta1 is therefore expected to have clinical benefits in disorders where immune responses are impaired or ineffective, such as acute and chronic infections, cancers, and vaccine non-responsiveness, all of which are hallmarks of an impaired or inadequate immune response. Importantly, Ta1 acts without overstimulation of cytokine production and is generally well tolerated; it has an excellent safety profile and does not appear to induce the side effects and toxicities commonly associated with agents in this class such as interferonalpha and interleukin-2.
No takes yet. Share an insight, caveat, or question.
Cynthia W. Tuthill Robert S. King (2013) studied this question.